Tilray Brands (TLRY) Cash from Investing Activities (2017 - 2026)
Tilray Brands' (TLRY) quarterly Cash from Investing Activities came in at -$51.2 million in Q2 2026, down 478.51% YoY from $13.5 million in Q2 2025, and down 276.99% on a QoQ basis from $28.9 million in Q1 2026.
Tilray Brands (TLRY) Cash from Investing Activities (2017 - 2026) Analysis & Trends
Tilray Brands (TLRY) has 10 years of Cash from Investing Activities data on file, last reported at -$51.2 million in Q2 2026.
- Quarterly Cash from Investing Activities fell 478.51% year-over-year to -$51.2 million in Q2 2026, while the trailing twelve-month figure through May 2026 was -$55.8 million (down 19.44% YoY) and the FY2026 annual result came in at -$55.8 million, down 19.44% from the prior year.
- Cash from Investing Activities slipped to -$51.2 million in Q2 2026, from $28.9 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $81.5 million in Q4 2023 to a low of -$271.4 million in Q4 2022.
- A 5-year average of -$14.7 million and a median of -$3.1 million in 2022 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities tumbled 3792.69% — and 2026, when it soared 24400.0%.
- Tracing TLRY's Cash from Investing Activities over 5 years: stood at -$271.4 million in 2022, then surged by 130.03% to $81.5 million in 2023, then tumbled by 113.16% to -$10.7 million in 2024, then tumbled by 440.84% to -$58.0 million in 2025, then grew by 11.77% to -$51.2 million in 2026.
- The last three Cash from Investing Activities figures came in at -$51.2 million (Q2 2026), $28.9 million (Q1 2026), and -$58.0 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -491.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -300.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -550.24 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 87.50 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -51.60 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -135.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -110.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Tilray Brands | 523.93 Mn | 289.30 Mn | 90.52 Mn | -51.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | -51.18 Mn |
| May 31, 2026 | -51.18 Mn |
| Feb 28, 2026 | 28.92 Mn |
| Feb 28, 2026 | 28.92 Mn |
| Nov 30, 2025 | -58.01 Mn |
| Nov 30, 2025 | -58.01 Mn |
| Aug 31, 2025 | 24.47 Mn |
| Aug 31, 2025 | 24.47 Mn |
| May 31, 2025 | 13.52 Mn |
| May 31, 2025 | 13.52 Mn |
| Feb 28, 2025 | -119,000.00 |
| Feb 28, 2025 | -119,000.00 |
| Nov 30, 2024 | -10.73 Mn |
| Nov 30, 2024 | -10.73 Mn |
| Aug 31, 2024 | -49.40 Mn |
| Aug 31, 2024 | -49.40 Mn |
| May 31, 2024 | 45.06 Mn |
| May 31, 2024 | 45.06 Mn |
| Feb 29, 2024 | 28.09 Mn |
| Feb 29, 2024 | 28.09 Mn |